Skip to content

Author

James P. MacNamara

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Decreases in Left Atrial Strain with Mavacamten Therapy and Associations with Atrial Fibrillation.

BACKGROUND In obstructive hypertrophic cardiomyopathy (oHCM), the cardiac myosin inhibitor (CMI) mavacamten improves left ventricular outflow tract (LVOT) obstruction and functional capacity. Symptoms and exertional capacity in oHCM are also influenced by left atrial function, commonly assessed by left atrial strain (L...

Myra Lewontin, Yaqub Betz, Kenneth C. Bilchick et al. · 0 citations
Review Jul 2026

Targeted Therapies in Hypertrophic Cardiomyopathy: A Practical Review of Evidence, Implementation, and Innovation.

Hypertrophic cardiomyopathy (HCM) is a common inherited disorder characterized by sarcomere dysfunction leading to myocardial hypertrophy, diastolic impairment, and, in many patients can result in dynamic left ventricular outflow tract obstruction (LVOTO). Traditional pharmacologic management of HCM has relied on β-blo...

Madeline Smoot, James P. MacNamara, Michael P Ayers · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.